Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 21;17(11):e0278040.
doi: 10.1371/journal.pone.0278040. eCollection 2022.

Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study

Yi-Feng Wu  1   2   3 , Ming-Huei Gu  4 , Chao-Zong Liu  5 , Wei-Han Huang  1   6 , Sung-Chao Chu  1   2 , Tso-Fu Wang  1   2
Affiliations

Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study

Yi-Feng Wu et al. PLoS One. .

Abstract

Objectives: Myelodysplastic syndrome (MDS) is a heterogeneous hematopoietic stem cell disorder with thrombocytopenia. Flow cytometric immunophenotyping of blood cells has been instrumental in diagnosis as co-criteria, but the data regarding platelets remains lacking. This study aims to determine if there is a difference in surface antigen levels on platelets by comparing surface antigen levels in MDS patients and healthy control subjects. Concurrently, as flow cytometric gating can reveal the diameter of cells, this study will investigate differences in giant platelet percentage by comparing these percentages in high- and low-risk MDS patients.

Study design: Twenty newly diagnosed MDS patients were enrolled in this study. Platelet surface antigen levels were determined by measuring the binding capacity of antibodies with flow cytometry.

Results: Platelets of MDS patients were shown to have a lower level of CD61 and higher levels of CD31 and CD36 than healthy controls. Judged by forward scatter (FSC), MDS patients' platelets appeared to be larger than those of healthy control subjects, whereas the MFI adjusted by diameter (MFI/FSC ratio) of CD31, CD41a, CD42a, CD42b and CD61 on platelets were lower in MDS patients than in healthy control subjects. There was a significant quantity of giant platelets found in MDS patients, and the high-risk MDS patients tended to have a higher percentage of giant platelets than low-risk patients. Conclusions: All the results indicate that MDS patients exhibit a lower antigen presentation (MFI) adjusted by diameter on platelets than healthy controls and the giant platelets detected by flow cytometry might correlate with the condition of MDS.

PubMed Disclaimer

Conflict of interest statement

NO - The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
(A) The level (MFI) of CD31, CD36, CD41a, CD42a, CD42b and CD61 on the platelets of MDS patients (MDS, n = 20) and healthy controls (HC, n = 20). (B) The MFI adjusted by diameter (MFI/FSC) of CD31, CD36, CD41a, CD42a, CD42b and CD61 on the platelets of MDS patients (MDS, n = 20) and healthy controls (HC, n = 20). Data were shown in mean±SD. An unpaired t-test was employed to examine the difference between MDS patients and healthy controls. * P-value <0.05; ** P-value <0.001.
Fig 2
Fig 2
(A) The gating of flow cytometry with platelets from an MDS patient. (B) The gating of flow cytometry with platelets from a healthy control.
Fig 3
Fig 3. The percentage of giant platelets in healthy controls and patients with low-risk and high-risk MDS.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002:136–61. doi: 10.1182/asheducation-2002.1.136 . - DOI - PubMed
    1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872–85. doi: 10.1056/NEJMra0902908 . - DOI - PubMed
    1. van Spronsen MF, Westers TM, Rozema H, Ossenkoppele GJ, Kibbelaar RE, Hoogendoorn M, et al.. Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes. Am J Hematol. 2017;92(11):E631–e4. doi: 10.1002/ajh.24867 . - DOI - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. doi: 10.1182/blood-2016-03-643544 . - DOI - PubMed
    1. van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, et al.. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma. 2013;54(3):472–5. doi: 10.3109/10428194.2012.718341 . - DOI - PubMed

Publication types